Skip to main content

Table 1 Demographic and Disease Characteristics of the Patients at Baseline

From: A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

Characteristics Docetaxel-sunitinib (N = 33) Docetaxel alone (N = 35) Overall (N = 68)
Gender
 Male 11 (33.3%) 13 (37.1%) 24 (35.3%)
 Female 22 (66.7%) 22 (62.9%) 44 (64.7%)
Mean age (range), years 55.4 (34.0–76.0) 57.1 (35.7–74.5) 56.3 (34.0–76.0)
Race
 Chinese 28 (84.8%) 17 (48.6%) 44 (66.2%)
 Indian 0 (0%) 3 (8.6%) 3 (4.4%)
 Malay 4 (12.1%) 11 (31.4%) 15 (22.1%)
 Others 1 (3.0%) 4 (11.4%) 5 (7.4%)
Site of primary tumour
 Breast 16 (48.5%) 17 (48.6%) 33 (48.5%)
 Lung 12 (36.4%) 13 (37.1%) 25 (36.8%)
 Others 5 (15.2%) 5 (14.3%) 10 (14.7%)
`Histology
 Adenocarcinoma 16 (48.5%) 20 (57.1%) 36 (52.9%)
 Squamous carcinoma 13 (39.4%) 12 (34.3%) 25 (36.8%)
 Others (including poorly differentiated, NOS, lymphoma, small cell) 4 (12.1%) 3 (8.6%) 7 (10.3%)
Lines of prior palliative therapy
 0 10 (30.3%) 11 (31.4%) 21 (30.9%)
 1 12 (36.4%) 10 (28.6%) 22 (32.4%)
 2 6 (18.2%) 8 (22.9%) 14 (20.6%)
 3 4 (12.1%) 2 (5.7%) 6 (8.8%)
 4 1 (3.0%) 2 (5.7%) 3 (4.4%)
 >/=5 0 (0%) 2 (5.7%) 2 (3.0%)
\